# **Indicator Analysis 2021**

# Annual Report of the Certified Neuro-oncology Cancer Centres

Audit year 2020 / Indicator year 2019






## Table of Contents

Introduction	3
General information	3
Status of the certification system for Neuro-oncology Cancer Centres 2020	5
Clinical sites taken into account	6
Tumour documentation systems at the Centres' clinical sites	7
Analysis of basic data	8
Analysis of indicators	9
Indicator No. 1: Number of primary cases	9
Indicator No. 2: Interdisciplinary case reviews	10
Indicator No. 3: Psycho-oncological care	11
Indicator No. 4: Counselling social services	12
Indicator No. 5: Study participation	13
Indicator No. 6a: Surgical primary cases	14
Indicator No. 6b: Biopsy	15
Indicator No. 7a: Revision surgeries	16
Indicator No. 7b: Clinically symptomatic secondary bleeding	17
Indicator No. 8: Post-surgical wound infections	18
Imprint	19

## **General information**



	Indicator definition	All clinica	al sites 2019	
		Median		Range
Numerator	Primary cases (elective patients:pre-intervention. emergency patients: post- intervention) who were presented in the tumour conference	172*	74 - 588	9,366
Denominator	Primary cases (= Indicator 1)	184.5*	109 - 607	9,914
Rate	Target value ≥ 95%	96.81%	39.36% - 100%	94.47%**



### **Basic data indicator:**

The definition of the numerator, denominator and the target value are taken from the indicator sheet.

The specification of the median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

Under Range, the value range for the numerator, denominator and ratio of all centers is specified.

The Total Patients column displays the total of all patients treated according to the indicator and the corresponding quota.

#### **Diagram:**

The x-axis indicates the number of Centres, the y-axis gives the values in percent or number (e.g. primary cases). The target value is depicted as a horizontal green line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.


## **General information**





## **Cohort development:**

The **cohort development** in the years **2015**, **2016**, **2017**, **2018** and **2019** is presented in a box plot diagram.



## **Box plot:**

A box plot consists of a **box with median**, **whiskers** and **outliers**. 50 percent of the Centres are within the box. The median divides the entire available cohort into two halves with an equal number of Centres. The whiskers and the box encompass a 90<sup>th</sup> percentile area/range. The extreme values are depicted here as dots.



## Status of the certification system for Neuro-oncology Cancer Centres 2020

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Ongoing procedures	5	2	2	5	8	4
Certified Centres	46	42	38	32	26	21
Certified clinical sites	47	43	39	33	27	22
Neuro-oncology Cancer Centres with						
1 clinical site	45	41	37	31	25	20
2 clinical sites	1	1	1	1	1	1
3 clinicial sites	0	0	0	0	0	0
4 clinical sites	0	0	0	0	0	0



## Clinical sites taken into account

	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016	31.12.2015
Clinical sites included in the Annual Report	44	40	38	30	24	19
equivalent to	93.6%	93.0%	97.4%	90.9%	88.9%	86.4%
Primary cases total*	9,914	9,254	8,820	7,219	5,067	3,952
Primary cases per clinical site (mean)*	225.3	231.4	232.1	240.6	211.1	208
Primary cases per clinical site (median)*	184.5	201.5	192.5	214	202.5	213

\*The figures are based on the clinical sites listed in the Annual Report.


This annual report looks at the neuro-oncological centers certified in the certification system of the German Cancer Society. The basis for the diagrams in the annual report is the data sheet.

The annual report includes 44 of the 47 certified center locations. Excluded are 3 sites that were certified for the first time in 2020 (data mapping of the complete calendar year is not mandatory for initial certifications). In all 47 sites 10278 primary neuro-oncological cases were treated. An up-to-date overview of all certified sites is available at <u>www.oncomap.de</u>

The indicators published here relate to the indicator year 2019 and provide the basis for the audits conducted in 2020.



## Tumour documentation systems in the Centre's clinical sites



Andere = other Eigenentwicklung = intrinsic development Tumorzentrum = tumour centre


The information on the tumour documentation system was taken from the data sheet (Basic Data Sheet). It is not possible to specify several systems. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.




## **Basic data – Stage distribution primary cases**

Benign neoplasm

cases




cases



Unclear behaviour

(ICD-O-3 Morphology: .../1)




	Benign neoplasms (ICD-O-3 Morphology:/0)					Malignant neoplasms (ICD-O-3 Morphology:/3)				Uncertain growth behaviour (ICD-O-3 Morphology:/1)			
	C70	C71	C72	C75	C70	C71	C72	C75	C70	C71	C72	C75	
Non-surgical	666 (21.37%)	64 (23.36%)	213 (22.71%)	227 (18.20%)	1 (2.86%)	926 (27.26%)	39 (28.68%)	3 (13.04%)	7 (2.16%)	39 (14.77%)	6 (5.61%)	6 (11.54%)	2,197
Surgical	2,451 (78.63%)	210 (76.64%)	725 (77.29%)	1,020 (81.80%)	34 (97.14%)	2.471 (72.74%)	97 (71.32%)	20 (86.96%)	317 (97.84%)	225 (85.23%)	101 (94.39%)	46 (88.46%)	7,717
Primary cases total	3,117 (100%)	274 (100%)	938 (100%)	1,247 (100%)	35 (100%)	3,397 (100%)	136 (100%)	23 (100%)	324 (100%)	264 (100%)	107 (100%)	52 (100%)	9,914

C70: neoplasm of meninges; C71: neoplasm of brain; C72: neoplasm of medulla and cerebral nerves; C75: Other endocrine glands and related structures in line with ICD-O-3 topography




## 1. Number of primary cases



	Indicator definition	All clinical sites 2019						
		Median	Range	Patients Total				
Number	Primary cases def. in line with 1.2.1	184.5	109 - 607	9,914				
	Target value ≥ 100							

Sollvorgabe = target value



		2015	2016	2017	2018	2019
•	Max	503.00	613.00	630.00	616.00	607.00
Т	95 <sup>th</sup> percentile	405.20	444.25	448.35	436.70	434.00
	75 <sup>th</sup> percentile	243.25	290.25	279.50	276.25	291.50
	Median	202.50	214.00	192.50	201.50	184.50
	25 <sup>th</sup> percentile	139.75	162.00	158.00	143.75	149.00
T	5 <sup>th</sup> percentile	108.75	118.15	118.65	132.85	115.75
•	Min	104.00	110.00	111.00	115.00	109.00

Clinical sites evaluable dat		Clinical sites the target value	•
Number	%	Number	%
44	100.00%	44	100.00%

#### Comments:

All centres achieve the target of at least 100 primary cases. A total of 9,384 primary cases were treated in the German centres. Overall, the number of primary cases treated in certified centres (also outside Germany) increases by 7.13% compared to the pre-indicator year.



## 2. Interdisciplinary case reviews

Rate										
100%	Median 96,81%						Indicator definition	All clinica	al sites 2019	
90%	Sollvorgabe ≥ 95%							Median		Range
80%								meanan		Range
70% 60%						Numerator	Primary cases (elective patients:pre-intervention. emergency patients: post- intervention) who were	172*	74 - 588	9,366
50% 40%							presented in the tumour board			
30% 20%						Denominator	Primary cases (= Indicator 1)	184.5*	109 - 607	9,914
10%										
0										
	Sollvorgabe = target value	10	20	30	40 44 clinical sites	Rate	Target value ≥ 95%	96.81%	39.36% - 100%	94.47%**

100% 2015 2016 2017 2018 90% Max 100% 100% 100% 100% 80% 70% 95<sup>th</sup> percentile 99.91% 99.55% 100% 100% 60% 75<sup>th</sup> percentile 97.71% 98.35% 98.77% 98.71% 50% 96.02% 96.95% 40% Median 96.36% 96.72% 30% 25th percentile 91.32% 94.91% 86.46% 93.77% 20% 5<sup>th</sup> percentile 39.84% 47.96% 57.56% 71.30% 10% Min 24.65% 20.87% 22.52% 24.11% 2015 2016 2017 2018 2019

Clinical sites evaluable dat		Clinical sites the target val	•
Number	%	Number	%
44	100.00%	36	81.82%

#### Comments:

2019

100%

100%

98.35%

96.81%

95.67%

68.52%

39.36%

The presentation rate in the tumour board continues to increase at a high level. Only 8 centres (previous year: 10) failed to meet the target of at least 95%, which was mainly due to organisational problems (e.g. SOP not followed) and missing processes for the post-interventional presentation of emergency patients. The auditors worked on adjustments to the processes (e.g. through training, SOP) and issued a remark if necessary.

\*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort. \*\* Percentage of total patients treated in centers according to the numerator.



## 3. Psycho-oncological care


Rate															
70%	Begründungspflicht > 75%									Indica	ator definition	All clinical	sites 2019		
60%												Median	Range	Patients Total	
50%								Numera			ry cases who ed psycho-	53*	12 - 199	3,060	
40%										an inp	ogical care in atient or				
30% -	Median 21,76%										tient setting ultation ≥ 25				
20%	Regründungenflight - 10%							Denomin		,	m	004 5*	123 - 732	40,400	
10%	Begründungspflicht < 10%							Denomina		Indica	ry cases (= tor 1) and	234.5*	123 - 732	12,483	
0	10	20		30		40				patien recurr	its with ence				
В	Begründungspflicht = mandatory statement for reasons				44 clinical sites Rate					atory statement sons*** < 10% 75%	21.76%	7.68% - 72.82%	24.51%**		
80%	• •	•			2015	2016	2017	2018	2018 2019		Clinical sites wie valuable data			es within the limits	
70%	•		•	Max	77.18%	77.19%	60.49%	64.23%	72.82%	6	Number	%	Number	%	
60% 50%		т	Т	95 <sup>th</sup> percentile	54.83%	54.36%	53.87%	52.44%	54.19%	6	44	100.00%	41	93.18%	
40%				75 <sup>th</sup> percentile	28.36%	31.00%	29.37%	29.70%	33.14%	6	Comments:				
30%				Median	16.75%	18.24%	21.63%	18.46%	21.76%	6	The overall attendar previous year. Also	, only 3 centres (	(previous year: 4) ar	e still below the	
30%											10% limit, which g consultation. The c				
20%	· · · · · · · · · · · · · · · · · · ·			25 <sup>th</sup> percentile	10.11%	13.03%	12.68%	13.06%	13.06% 17.18% proportion of benign findings wi counselling, as well as consultation			gn findings with I as consultatior	a correspondingly as with external psy	low need for chooncologists.	
10%		$\downarrow$	$\perp$	5 <sup>th</sup> percentile	7.89%	2.26%	5.16%	The centres		The centres reacted often and better inter					
	2015 2016 2017 2018	2019	•	Min	1.68%	1.52%	1.31%	4.27%	7.68%	, D					

The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort. \*\* Percentage of total patients treated in centers according to the numerator.

\*\*\* For values outside the plausibility limit(s), the centers are required to provide a justification.



## 4. Counselling social services



100%	<b>╀ ╀ ♥ ₽ ●</b>		
90% -			
80% -		•	Max
70% - 60% -		Т	95 <sup>th</sup> perc
50%-			75 <sup>th</sup> perc
40% -			Median
30% - 20% -	• - +		25 <sup>th</sup> perc
10% -	•	$\perp$	5 <sup>th</sup> perce
-	2015 2016 2017 2018 2019	•	Min

		2015	2016	2017	2018	2019
•	Max	100%	99.01%	99.04%	100%	94.95%
Т	95 <sup>th</sup> percentile	98.06%	96.35%	91.51%	96.18%	83.80%
	75 <sup>th</sup> percentile	79.37%	78.87%	71.95%	69.13%	63.62%
	Median	63.22%	66.75%	61.47%	53.51%	51.96%
	25 <sup>th</sup> percentile	52.49%	47.72%	47.74%	43.81%	42.93%
L	5 <sup>th</sup> percentile	43.33%	35.70%	32.92%	31.11%	30.65%
•	Min	37.99%	28.14%	22.26%	19.25%	29.10%

Clinical sites evaluable dat		Clinical sites within the plausibility limits				
Number	%	Number	%			
44	100.00%	42	95.45%			

#### Comments:


Social work counselling services are very well implemented in the centres. The two centres below the 30% limit fall just short of it. Both could not name any concrete reasons for the comparatively low counselling rate, but announced more intensive efforts to offer low-threshold counselling.

The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.



## 5. Study participation



	Indicator definition	All clinic	All clinical sites 2019				
		Median	Range	Patients Total			
Numerator	All patients (malignant and benign) included in a study with an ethic vote	25*	0 – 1,430	4,276			
Denominator	Malignant primary cases	63*	34 - 148	3,591			
Rate	Target value ≥ 5%	40.67%	0.00% - 966.22%	119.08%**			

Sollvorgabe = target value

1000%	•			2015	2016	2017	2018	2019
900% - 800% -	•	•	Мах	<mark>578.26%</mark>	<mark>601.06%</mark>	601.09%	787.88%	<mark>966.22%</mark>
700% -		Т	95 <sup>th</sup> percentile	<mark>316.37%</mark>	<mark>288.98%</mark>	<mark>233.18%</mark>	<mark>232.51%</mark>	<mark>346.81%</mark>
600% - 500% -	• • •		75 <sup>th</sup> percentile	47.95%	46.20%	63.76%	74.11%	79.34%
400% -			Median	21.75%	26.87%	29.22%	34.13%	40.67%
300% -	ΤΤ	Ц	25 <sup>th</sup> percentile	8.14%	9.62%	14.95%	17.39%	19.55%
200% - 100% -		$\perp$	5 <sup>th</sup> percentile	0.33%	6.44%	6.19%	8.51%	6.46%
				0.00%	5 61%	5.04%	3 39%	0.00%
-	2015 2016 2017 2018 2019	•	Min	0.00%	5.61%	5.04%	3.39%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value				
Number	%	Number	%			
44	100.00%	42	95.45%			


#### Comments:

The overall study quota has risen further, which is mainly due to individual centres with extraordinarily high values. Two centres (previous year: one) failed to meet the target of at least 5% study enrolment measured against the number of primary cases. In one case, a planned study was delayed in starting. The centre with a quota of 0% initiated its own study, for which, however, the ethics vote was still pending. In the audits, both centres expected significantly higher rates in the following year. Due to the prospective exclusion of pure biobank collections, a lower dispersion of the individual values can also be expected for the future.

\*The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort. \*\* Percentage of total patients treated in centers according to the numerator.



## 6a. Surgical primary cases



	Indicator definition	All clinical sites 2019				
		Median	Range	Patients Total		
Number	Surgical primary cases def. in line with 5.2.3.a	140	72 - 601	7,717		
	Target value ≥ 60					

Sollvorgabe = target value

 $\begin{array}{c}
700 \\
600 \\
500 \\
400 \\
300 \\
200 \\
100 \\
2015 2016 2017 2018 2019
\end{array}$ 

		2015	2016	2017	2018	2019
•	Max	493.00	605.00	626.00	610.00	601.00
Т	95 <sup>th</sup> percentile	308.35	368.75	356.75	375.70	344.85
	75 <sup>th</sup> percentile	224.50	241.00	223.50	233.75	208.25
	Median	159.50	171.50	165.00	147.00	140.00
	25 <sup>th</sup> percentile	124.25	129.00	118.00	114.25	112.00
	5 <sup>th</sup> percentile	92.90	100.35	89.00	85.00	84.30
•	Min	81.00	87.00	74.00	67.00	72.00
•						


Clinical sites evaluable dat		Clinical sites meeting the target value				
Number	%	Number	%			
44	100.00%	44	100.00%			

#### Comments:


As in the previous year, all centres easily meet the minimum requirement of 60 primary surgical cases. Despite a further decline in the median, which is often observed with the increasing establishment of a certification system, the overall picture is stable. The number of primary surgical cases shown in the annual report increased by 3.93%.



## 6b. Biopsy



	Indicator definition	All clinical sites 2019				
		Median	Range	Patients Total		
Number	Biopsies def. in line with 5.2.3b	22	3 - 140	1,431		
	No target value					



		2015	2016	2017	2018	2019
•	Max	62.00	125.00	135.00	136.00	140.00
Г	95 <sup>th</sup> percentile	61.25	86.80	91.90	79.00	93.80
	75 <sup>th</sup> percentile	34.50	37.50	36.00	37.25	41.25
	Median	24.50	27.50	27.00	23.50	22.00
	25 <sup>th</sup> percentile	14.50	16.50	15.25	15.75	14.00
	5 <sup>th</sup> percentile	7.15	11.45	6.85	5.00	6.30
	Min	2.00	10.00	6.00	4.00	3.00
	25 <sup>th</sup> percentile	14.50 7.15	16.50 11.45	15.25 6.85	15.75 5.00	14.0 6.3

Clinical sites with evaluable data		Clinical sites meeting the target value			
Number	%	Number	%		
44	100.00%				

#### Comments:

The number of biopsies increased quite significantly by 16.15% compared to the previous year. The spread of the individual values has increased further. Since there is no target for this indicator, there are no explanations from the centres as to the reasons for these differences.



## 7a. Revision surgeries

Rate								
10%	Begründungspflicht > 10%		_		Indicator definition	All clinica	l sites 2019	
9% 8%		_				Median	Range	Patients Total
7% 6%	Median 5,45%			Numerator	merator Revision surgeries as a consequence of post-	9*	0 - 25	423
5% 4%		ian 5,45%						
3% 2% 1%	Begründungspflicht < 1%			Denominator	Surgical primary cases (= Indicator 6a)	140*	72 - 601	7,717
0	10 20 Begründungspflicht = mandatory statement for reasons	30	40 44 clinical sites	Rate	Mandatory statement of reasons*** < 1% and >10%	5.45%	0.00% - 9.85%	5.48%**

12%	•
10% -	• ⊤ <u>+</u> ⊤ <u>+</u> +
8%-	
6% -	
4% -	┯┯┯┯
2% -	
	2015 2016 2017 2018 2019

		2015	2016	2017	2018	2019
•	Max	11.88%	9.70%	10.81%	9.20%	9.85%
Т	95 <sup>th</sup> percentile	9.87%	8.94%	9.59%	9.03%	9.38%
	75 <sup>th</sup> percentile	8.58%	6.79%	6.45%	6.88%	7.29%
	Median	6.63%	5.09%	5.51%	5.09%	5.45%
	25 <sup>th</sup> percentile	4.47%	3.64%	3.57%	3.39%	4.19%
$\bot$	5 <sup>th</sup> percentile	1.31%	2.26%	2.28%	2.01%	1.18%
•	Min	0.97%	0.85%	2.03%	1.83%	0.00%

Clinical sites evaluable dat		Clinical sites within the plausibility limits			
Number	%	Number	%		
44	100.00%	42	95.45%		

#### Comments:

The two centres outside the plausibility limits had no or only one revision procedure below the lower plausibility limit of 1%, i.e. they had an extraordinarily low revision rate. These excellent results could be confirmed with populations of 120 and 106 primary surgical cases in the audits. Overall, the revision rate is at a consistently good level.

The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

\*\*\* For values outside the plausibility limit(s), the centers are required to provide a justification.



## 7b. Clinically symptomatic secondary bleeding

Rate Begründungspflicht > 10%							
10%				Indicator definition	All clinical s	ites 2019	
9% 8%		_			Median	Range	Patients Total
7% 6%			Numerator	Surgical primary cases with clinically symptomatic secondary	3*	0 - 17	213
5% 4%				bleeding (= new onset or worsening of an existing neurological disorder)			
3% - Median 1,96%							
2% Weduan 1,90% 1% Begründungspflicht < 1%			Denominator	Surgical primary cases (= Indicator 6a)	140*	72 - 601	7,717
0 10 20 Begründungspflicht = mandatory statement for reasons	30	40 44 clinical sites	Rate	Mandatory statement of reasons*** < 1% and >10%	1.96%	0.00% - 7.58%	2.76%**

9%		•			
8% -			•	•	
7% -		Т	T	-	
6% -	•			Т	
5% -					
4% -					
3% -					
2% -					
1% -			$\top$		
	<u> </u>	-			
1	2016	2017	2018	2019	

		2015	2016	2017	2018	2019
•	Max		6.15%	8.85%	7.60%	7.58%
Γ	95 <sup>th</sup> percentile		5.56%	7.32%	6.84%	5.93%
	75 <sup>th</sup> percentile		3.68%	3.78%	3.87%	3.90%
	Median		2.54%	1.88%	2.71%	1.96%
	25 <sup>th</sup> percentile		1.54%	1.28%	1.43%	1.38%
L	5 <sup>th</sup> percentile		0.35%	0.43%	0.00%	0.11%
	Min		0.00%	0.00%	0.00%	0.00%

Clinical sites evaluable dat		Clinical sites within the plausibility limits			
Number	%	Number	%		
44	100.00%	39	88.64%		

#### Comments:

Similar to indicator 7a, the 5 centres outside the plausibility limits show extraordinarily good values, in this case related to clinically symptomatic rebleeding. Even after checking the values, the audits showed that 3 of these centres had no post-operative bleeding and 2 only one. The overall postbleeding rate also decreased slightly, both on average and in the median.

The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator.

\*\*\* For values outside the plausibility limit(s), the centers are required to provide a justification.



## 8. Post-surgical wound infections

Rate Begründungspflicht > 10%								
10%					Indicator definition	All clinica	al sites 2019	
9% 8%						Median	Range	Patients Total
7% 6% - 5% 4% 3%				Numerator	Surgical primary cases with post-surgical meningitis confirmed by laboratory tests and/or a wound infection requiring surgical revision within 30d of surgery	2*	0 - 16	137
2% Median 1,52% Begründungspflicht < 1%				Denominator	Surgical primary cases (= Indicator 6a)	140*	72 - 601	7,717
10 Begründungspflicht = mandatory stater	20 ment for reasons	30	40 44 clinical sites	Rate	Mandatory statement of reasons*** < 1% and >10%	1.52%	0.00% - 4.64%	1.78%**

9%	•
8% -	•
7% -	•
6% -	•
5%-	T     •
4% -	
3% -	
2% -	
1%-	
+	2015 2016 2017 2018 2019

		2015	2016	2017	2018	2019
1	Max	8.70%	6.48%	8.02%	5.88%	4.64%
-	95 <sup>th</sup> percentile	4.90%	5.47%	5.47%	3.88%	4.19%
	75 <sup>th</sup> percentile	3.26%	3.03%	2.54%	2.41%	2.96%
	Median	2.04%	1.85%	1.51%	1.47%	1.52%
	25 <sup>th</sup> percentile	1.32%	0.86%	0.86%	0.82%	0.82%
-	5 <sup>th</sup> percentile	0.05%	0.00%	0.28%	0.00%	0.00%
	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites version of the comparison of the		Clinical sites within the plausibility limits			
Number	%	Number	%		
44	100.00%	31	70.45%		

#### Comments:

Both the median and the upper percentage ranges show further improvements compared to the previous year. Here, too, 13 centres stood out with particularly good values of less than 1%. These are often the result of many years of efforts by the centres to optimise surgical procedures and regular evaluation of the indicators.

The median for numerator and denominator does not refer to an existing center, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

\*\* Percentage of total patients treated in centers according to the numerator. \*\*\* For values outside the plausibility limit(s), the centers are required to provide a justification.

## WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on www.krebsgesellschaft.de

#### **Authors**

German Cancer Society (DKG) Certification Committee for Neuro-oncology Cancer Centres Uwe Schlegel. Spokesman Certification Committee Walter Stummer, Deputy Spokesman Certification Committee Simone Wesselmann, German Cancer Society (DKG) Johannes Rückher, German Cancer Society (DKG) Ellen Griesshammer, German Cancer Society (DKG) Viktoria Schumakov, OnkoZert GmbH Florina Dudu, OnkoZert GmbH Julia Ferencz, OnkoZert GmbH

#### Imprint

Publisher and responsible for content: Deutsche Krebsgesellschaft (DKG) Kuno-Fischer-Straße 8 14057 Berlin Tel.: +49 (030) 322 93 29 0 Fax: +49 (030) 322 93 29 66 Vereinsregister Amtsgericht Charlottenburg, Vereinsregister-Nr.: VR 27661 B V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with: OnkoZert, Neu-Ulm www.onkozert.de

Version e-A1-de; Stand 13.07.2021

# **ISBN:** 978-3-948226-55-8